On February 8, 2021, Neos Therapeutics, Inc. (NasdaqGM:NEOS) closed the transaction. The transaction got approved by the Nasdaq Stock Market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.86 USD | -0.69% |
|
+2.14% | +0.70% |
05-15 | Transcript : Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024 | |
05-15 | Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.70% | 17.2M | |
+55.95% | 811B | |
+43.62% | 640B | |
-6.98% | 353B | |
+19.08% | 333B | |
+9.05% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.91% | 168B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc.